Dataset features


Application: Gene expression microarray analysis
Number of samples: 88
Release date: Apr 30 2017
Last update date: Oct 29 2018
Access: Public
Diseases: Lymphoma, Lymphoma, Follicular, Neoplasms
Chemicals: Tyrosine
Dataset link Expression data from DLBCL tumor biopsies

Experimental Protocol

Gene expression in ibrutinib pretreated tumor biopsy samples from ABC-DLBCL patients was detected by U133 plus 2.0 arrays and the correlation of BCL2 expression and patient response to ibrutinib or PFS after ibrutinib treatment was analyzed. There are total 28 ABC-DLBCL samples. 17 of them are non-responders (PD+SD) and 11 of them are responders (PR+CR). For this analysis restricted to ABC-DLBCL subtype, only the ABC-DLBCL samples were used and normalized separately. Data was processed with all subsets of DLBCL samples (60 samples) and also separately for 28 ABC-DLBCL samples ('re-analysis' samples). The values in the sample 'characteristics' field represent: response: CR=complete response, PR=partial response, SD=stable disease, PD=progression disease class: NR=non-responder, RR=responder subtype: ABC=ABC-DLBCL, GCB=GCB-DLBCL, UNC=unclassified subtype progression_free_survival_censor: censored case = 1; event (death/progression) = 0 in the censoring variable for the progression free survival analysis








Hsu-Ping Kuo